IN2014MN01892A - - Google Patents
Download PDFInfo
- Publication number
- IN2014MN01892A IN2014MN01892A IN1892MUN2014A IN2014MN01892A IN 2014MN01892 A IN2014MN01892 A IN 2014MN01892A IN 1892MUN2014 A IN1892MUN2014 A IN 1892MUN2014A IN 2014MN01892 A IN2014MN01892 A IN 2014MN01892A
- Authority
- IN
- India
- Prior art keywords
- dihydroquinazolin
- cyclodextrins
- piperazin
- methoxyphenyl
- arginine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/84—Nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102012101680A DE102012101680A1 (de) | 2012-02-29 | 2012-02-29 | Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat |
| PCT/EP2013/054114 WO2013127970A1 (de) | 2012-02-29 | 2013-02-28 | Pharmazeutische zubereitung enthaltend ein antiviral wirksames dihydrochinazolinderivat |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN01892A true IN2014MN01892A (es) | 2015-07-10 |
Family
ID=47757622
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1892MUN2014 IN2014MN01892A (es) | 2012-02-29 | 2013-02-28 |
Country Status (37)
| Country | Link |
|---|---|
| US (1) | US10603384B2 (es) |
| EP (3) | EP3556350B1 (es) |
| JP (1) | JP6387486B2 (es) |
| KR (1) | KR102149561B1 (es) |
| CN (2) | CN104144678A (es) |
| AU (1) | AU2013224947B2 (es) |
| BR (1) | BR112014020946B1 (es) |
| CA (1) | CA2865203C (es) |
| CL (1) | CL2014002306A1 (es) |
| CO (1) | CO7061076A2 (es) |
| CY (1) | CY1121910T1 (es) |
| DE (1) | DE102012101680A1 (es) |
| DK (2) | DK3556350T3 (es) |
| EA (1) | EA026584B1 (es) |
| ES (1) | ES2741698T3 (es) |
| FI (1) | FI3556350T3 (es) |
| HK (1) | HK1205462A1 (es) |
| HR (2) | HRP20240197T1 (es) |
| HU (1) | HUE045949T2 (es) |
| IL (1) | IL234363B (es) |
| IN (1) | IN2014MN01892A (es) |
| LT (2) | LT3556350T (es) |
| MA (1) | MA35941B1 (es) |
| ME (1) | ME03448B (es) |
| MX (1) | MX369666B (es) |
| MY (1) | MY172310A (es) |
| NZ (1) | NZ628444A (es) |
| PH (1) | PH12014501937A1 (es) |
| PL (2) | PL2819648T3 (es) |
| PT (2) | PT2819648T (es) |
| RS (2) | RS65137B1 (es) |
| SG (1) | SG11201405294XA (es) |
| SI (2) | SI3556350T1 (es) |
| TN (1) | TN2014000345A1 (es) |
| UA (1) | UA111415C2 (es) |
| WO (1) | WO2013127970A1 (es) |
| ZA (1) | ZA201405949B (es) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11864912B2 (en) | 2016-06-03 | 2024-01-09 | Atreya Innovations Private Limited | Device for the detection and reliable capturing of the pulse characteristics |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10319612A1 (de) * | 2003-05-02 | 2004-11-18 | Bayer Healthcare Ag | Substituierte Dihydrochinazoline |
| MX2015017758A (es) * | 2013-06-19 | 2016-06-21 | Aicuris Anti Infective Cures Gmbh | Letermovir amorfo y formulaciones farmaceuticas solidas del mismo para administracion por via oral. |
| US11091505B2 (en) | 2017-03-06 | 2021-08-17 | VenatoRx Pharmaceuticals, Inc. | Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof |
| UY39099A (es) | 2020-02-27 | 2021-08-31 | Aic246 Gmbh & Co Kg | 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] acetato de sodio y composiciones farmacéuticas del mismo |
| AR121438A1 (es) * | 2020-02-27 | 2022-06-08 | Aic246 Gmbh & Co Kg | Composiciones farmacéuticas que comprenden acetato de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] e iones de sodio |
| CN114539085B (zh) * | 2020-11-26 | 2023-10-20 | 山东诚创蓝海医药科技有限公司 | 一种脲基衍生物的制备 |
| CN115403528A (zh) * | 2021-05-27 | 2022-11-29 | 南京正大天晴制药有限公司 | 无定形3,4-二氢喹唑啉衍生物的制备方法 |
| CN113880776B (zh) * | 2021-11-16 | 2023-06-16 | 山东诚创蓝海医药科技有限公司 | 一种莱特莫韦中间体的制备方法 |
| AR128035A1 (es) | 2021-12-21 | 2024-03-20 | Aic246 Ag & Co Kg | Composiciones farmacéuticas que comprenden acetato de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] e iones de potasio |
| CN115322157B (zh) * | 2022-06-02 | 2023-12-05 | 浙江车头制药股份有限公司 | 来特莫韦中间体化合物及其制备方法和应用 |
| CN115677539B (zh) * | 2022-11-01 | 2023-10-24 | 南京工业大学 | 一种温和条件下钴催化脲基导向芳烃的高选择性单烯基化的方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1242699A (en) * | 1985-02-01 | 1988-10-04 | Bristol-Myers Company | Cefbuperazone and derivatives thereof |
| FR2585705B1 (fr) * | 1985-08-05 | 1989-01-13 | Bristol Myers Co | Sels de cephalosporine et compositions injectables |
| JP3552240B2 (ja) * | 1993-02-23 | 2004-08-11 | 第一製薬株式会社 | 高濃度ｔｃｆ製剤 |
| JPH11209277A (ja) * | 1998-01-19 | 1999-08-03 | Yoshitomi Pharmaceut Ind Ltd | 医薬組成物 |
| IT1304190B1 (it) * | 1998-12-18 | 2001-03-08 | Euphar Group Srl | Clatrati di deidroepiandrosterone e relative composizionifarmaceutiche |
| US7008945B1 (en) * | 1999-03-17 | 2006-03-07 | Astrazeneca Ab | Amide derivatives |
| WO2001091751A1 (en) * | 2000-05-30 | 2001-12-06 | Novo Nordisk A/S | New pharmaceutical composition and the process for its preparation |
| DE10319612A1 (de) | 2003-05-02 | 2004-11-18 | Bayer Healthcare Ag | Substituierte Dihydrochinazoline |
| AU2004293464A1 (en) * | 2003-11-25 | 2005-06-09 | Novartis Vaccines And Diagnostics, Inc. | Quinazolinone compounds as anticancer agents |
| DE602006004964D1 (de) | 2005-02-10 | 2009-03-12 | Bristol Myers Squibb Co | Dihydrochinazolinone als 5ht-modulatoren |
| DE102005027517A1 (de) * | 2005-06-15 | 2006-12-21 | Bayer Healthcare Ag | Verfahren zur Herstellung von Dihydrochinazolinen |
| US8743287B2 (en) * | 2009-07-24 | 2014-06-03 | Broadcom Corporation | Method and system for mitigating motion trail artifacts and improving low contrast contours in temporal filtering based noise reduction |
-
2012
- 2012-02-29 DE DE102012101680A patent/DE102012101680A1/de not_active Ceased
-
2013
- 2013-02-28 HU HUE13707000A patent/HUE045949T2/hu unknown
- 2013-02-28 PL PL13707000T patent/PL2819648T3/pl unknown
- 2013-02-28 BR BR112014020946-4A patent/BR112014020946B1/pt active IP Right Grant
- 2013-02-28 EP EP19176985.0A patent/EP3556350B1/de active Active
- 2013-02-28 EP EP24150976.9A patent/EP4328218A3/de active Pending
- 2013-02-28 FI FIEP19176985.0T patent/FI3556350T3/fi active
- 2013-02-28 SI SI201332077T patent/SI3556350T1/sl unknown
- 2013-02-28 DK DK19176985.0T patent/DK3556350T3/da active
- 2013-02-28 AU AU2013224947A patent/AU2013224947B2/en active Active
- 2013-02-28 ME MEP-2019-219A patent/ME03448B/me unknown
- 2013-02-28 ES ES13707000T patent/ES2741698T3/es active Active
- 2013-02-28 SG SG11201405294XA patent/SG11201405294XA/en unknown
- 2013-02-28 CN CN201380011670.7A patent/CN104144678A/zh active Pending
- 2013-02-28 MY MYPI2014002461A patent/MY172310A/en unknown
- 2013-02-28 IN IN1892MUN2014 patent/IN2014MN01892A/en unknown
- 2013-02-28 WO PCT/EP2013/054114 patent/WO2013127970A1/de active Application Filing
- 2013-02-28 JP JP2014559233A patent/JP6387486B2/ja active Active
- 2013-02-28 US US14/381,290 patent/US10603384B2/en active Active
- 2013-02-28 EP EP13707000.9A patent/EP2819648B1/de active Active
- 2013-02-28 RS RS20240135A patent/RS65137B1/sr unknown
- 2013-02-28 DK DK13707000.9T patent/DK2819648T3/da active
- 2013-02-28 PL PL19176985.0T patent/PL3556350T3/pl unknown
- 2013-02-28 UA UAA201410519A patent/UA111415C2/uk unknown
- 2013-02-28 EA EA201400963A patent/EA026584B1/ru unknown
- 2013-02-28 CA CA2865203A patent/CA2865203C/en active Active
- 2013-02-28 KR KR1020147023803A patent/KR102149561B1/ko active IP Right Grant
- 2013-02-28 LT LTEP19176985.0T patent/LT3556350T/lt unknown
- 2013-02-28 PT PT13707000T patent/PT2819648T/pt unknown
- 2013-02-28 RS RSP20191076 patent/RS59157B1/sr unknown
- 2013-02-28 MX MX2014010364A patent/MX369666B/es active IP Right Grant
- 2013-02-28 LT LTEP13707000.9T patent/LT2819648T/lt unknown
- 2013-02-28 CN CN201910661203.8A patent/CN110433166A/zh active Pending
- 2013-02-28 HR HRP20240197TT patent/HRP20240197T1/hr unknown
- 2013-02-28 SI SI201331541T patent/SI2819648T1/sl unknown
- 2013-02-28 PT PT191769850T patent/PT3556350T/pt unknown
- 2013-02-28 NZ NZ628444A patent/NZ628444A/en unknown
-
2014
- 2014-08-08 TN TNP2014000345A patent/TN2014000345A1/fr unknown
- 2014-08-13 ZA ZA2014/05949A patent/ZA201405949B/en unknown
- 2014-08-28 IL IL234363A patent/IL234363B/en active IP Right Grant
- 2014-08-28 PH PH12014501937A patent/PH12014501937A1/en unknown
- 2014-08-28 CO CO14189543A patent/CO7061076A2/es unknown
- 2014-08-29 CL CL2014002306A patent/CL2014002306A1/es unknown
- 2014-09-17 MA MA37360A patent/MA35941B1/fr unknown
-
2015
- 2015-06-25 HK HK15106080.1A patent/HK1205462A1/xx unknown
-
2019
- 2019-07-30 HR HRP20191369 patent/HRP20191369T1/hr unknown
- 2019-08-20 CY CY20191100885T patent/CY1121910T1/el unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11864912B2 (en) | 2016-06-03 | 2024-01-09 | Atreya Innovations Private Limited | Device for the detection and reliable capturing of the pulse characteristics |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MN01892A (es) | ||
| PH12015501964A1 (en) | Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c | |
| SG10201804552WA (en) | Nanoparticle compositions, formulations thereof, and uses therefor | |
| IN2015DN01156A (es) | ||
| PH12015501404B1 (en) | Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same | |
| WO2014004993A3 (en) | Methods of reducing ldl-p | |
| MX2014002171A (es) | Tratamientos de combinacion para hepatitis c. | |
| WO2011127333A3 (en) | Compounds for treating disease, for administering, and for pharmaceutical compositions | |
| MX356728B (es) | Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2. | |
| GEP20186880B (en) | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease | |
| MX2015015036A (es) | Metodos para mejorar los perfiles de lipidos utilizando atrasentan. | |
| MY168778A (en) | Oligonucleotide chelate complex-polypeptide compositions and methods | |
| MX2013002208A (es) | Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes. | |
| GEP20156332B (en) | Pyrazoles as crth2 antagonists | |
| AU2012307449A8 (en) | Sulfonic acid salts of heterocyclylamide-substituted imidazoles | |
| WO2012108794A3 (ru) | Производные 1,2,4-триазол-з-илтиогликолевой кислоты для применения в терапии | |
| RS54022B1 (en) | COMPOSITION OF VIRUS INHIBITOR FOR INVIVE THERAPEUTIC USE | |
| IN2013MU01245A (es) | ||
| IN2013MU01246A (es) | ||
| IN2013MU01244A (es) | ||
| IN2013MU01250A (es) | ||
| IN2013MU01249A (es) | ||
| IN2013MU01248A (es) | ||
| IN2013MU01247A (es) | ||
| IN2013MU01242A (es) |